Chidamide demonstrates significant single-agent activity and manageable toxicity in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), according to a recent study published online ahead of print in the Annals of Oncology.

Chinese researchers led by Yuan-Kai Shi, MD, PhD, of the Chinese Academy of Medical Sciences & Peking Union Medical College looked at 79 patients in a Chinese population with PTCL histology as part of a phase II study to examine the effects of chidamide, a novel oral benzamide class of histone deacetylase (HDAC) inhibitor.

Patients received chidamide orally twice a week, and primary endpoint was the overall response rate.

Continue Reading

Overall response rate was found to be 28 percent, including 14 percent of patients who had complete or unconfirmed complete response. Median progression-free survival was 2.1 months while overall survival was 21.4 months.

RELATED: Belinostat Monotherapy Safe, Effective for T-cell Lymphoma

Among the subtypes of PTCL observed, 13 percent who had angioimmunoblastic T-cell lymphoma were found to have higher overall as well as complete/unconfirmed complete response rate.

The results of the study “led to China Food and Drug Administration approval of chidamide in this indication,” according to the authors.


  1. Shi, Y., et al. “Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.” Annals of Oncology. doi: 10.1093/annonc/mdv237. [epub ahead of print]. June 23, 2015.